Alkem Laboratories has reported a consolidated net profit of ₹675 crore for the second quarter ended September 30, 2026, marking a drop of nearly 12 percent compared to the same period in the previous year.
Despite the decline in net profit, the company posted a total revenue from operations of ₹4,552 crore, representing a 13.8 percent increase year-on-year. According to Managing Director Sandeep Singh, the performance was driven by continued momentum in the domestic market, supported by execution across acute and chronic portfolios.
India sales contributed significantly to the top line, standing at ₹3,027 crore and registering a 9.5 percent growth over the previous year, accounting for over 60 percent of the company's total revenue. Meanwhile, international sales reached ₹1,454 crore, growing 22.3 percent despite ongoing pricing pressures in the US market, which were offset by volume growth.
The company's biotech segment experienced a setback during the quarter, with sales declining by 35 percent to ₹70 crore. Singh attributed this degrowth to the 'lumpy' nature of the contract development and manufacturing organization (CDMO) business. Enzene, Alkem's biologicals arm, and the newly expanded MedTech presence—bolstered by the addition of Occlutech—remain key strategic priorities. Medtech sales for the quarter stood at ₹133 crore, including Occlutech. Additionally, Dr. Amrut Naik was recently appointed as the Chief Executive Officer for the biologicals business.
On the regulatory front, Singh informed analysts that remediation efforts are currently underway at the Daman facility to address an Official Action Indicated (OAI) observation from the US Food and Drug Administration (USFDA). Separately, the USFDA inspection at the Mandva active pharmaceutical ingredients facility concluded without any Form 483 observations.
Alkem Laboratories closed the quarter ending September 30, 2026, with a net cash position of ₹4,905 crore.
"Alkem Laboratories' Q2 performance highlights a common reality in the pharmaceutical sector, where strong domestic demand and international volume growth can coexist with margin pressures and segment-specific volatility. The dip in biotech sales due to the lumpy nature of the CDMO model underscores the importance of revenue diversification. For growing enterprises, balancing core market execution with long-term strategic investments in biologicals and medtech—while actively managing regulatory compliance—remains critical to sustaining overall financial health." — Dr. Shishir Gupta, Founder & CEO, StartupLanes
Recent StartupLanes Articles
Browse through our 30 latest publications on venture capital, startups, and angel investing.